Advance Your Cancer Therapeutics Innovation: ACT Information Session
By: Crystal Carter
Texas A&M Innovation, in partnership with Therapeutic Labs @ TMC, invites researchers and biotech entrepreneurs to an Accelerator for Cancer Therapeutics (ACT) Information Session on October 20, 2026, from 1–2 p.m. CT. Sign up.
Discover how ACT helps advance promising cancer therapeutics from academic research toward clinical development through expert mentorship, specialized resources, and commercialization support.
The session will feature representatives from TMC Innovation, including Nelda Fikes, Jennifer Roohi, and Dr. Nassim Beiranvand, who will discuss program benefits such as grant writing assistance for CPRIT and SBIR/STTR funding, access to computational chemistry resources, and guidance in drug development, intellectual property, fundraising, business strategy, and investor readiness.
Applications for ACT’s 2026 cohort are open through October 30, 2026. Researchers interested in exploring potential projects may also request a one-on-one meeting with the ACT team by emailing ACT@tmc.edu.
Take the next step toward translating your research into meaningful patient impact.
Learn more about ACT or contact Amit Gupta at agupta@tamus.edu for additional information.
